中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2013年
11期
4713-4716
,共4页
前列腺肿瘤%肿瘤分期%血清YKL-40%Gleason评分
前列腺腫瘤%腫瘤分期%血清YKL-40%Gleason評分
전렬선종류%종류분기%혈청YKL-40%Gleason평분
Prostate neoplasms%Neoplasm staging%Serum YKL-40%Gleason scores
目的了解YKL-40与前列腺癌的发生、发展及转移的关系，旨在探讨YKL-40作为肿瘤标记物用于前列腺癌早期诊断、病情监测的价值。方法收集新诊断且未经治疗的前列腺癌患者血液标本40例，前列腺增生患者血液标本21例，健康对照组患者血液标本19例，采用酶联免疫吸附（ELISA）双抗体夹心法分别检测其血清YKL-40浓度。结果前列腺癌患者组、前列腺增生患者组和健康对照组的血清YKL-40浓度分别为（167.74±59.61）ng/ml，（118.84±25.81）ng/ml，（72.29±15.00）ng/ml，血清YKL-40浓度与临床分期有相关性（ P＜0.01），且在前列腺癌患者转移阶段呈高度表达，与Gleason评分无相关性。 YKL-40截断点为120.89 ng/ml时，灵敏度为86.7％，特异度为71.4％。结论 YKL-40在前列腺癌患者血清中的浓度显著高于前列腺增生患者和正常患者，提示检测YKL-40对前列腺癌诊断有一定的临床意义；血清YKL-40浓度对预测前列腺癌患者转移可能有重要的价值，可能参与了前列腺癌患者转移的过程。
目的瞭解YKL-40與前列腺癌的髮生、髮展及轉移的關繫，旨在探討YKL-40作為腫瘤標記物用于前列腺癌早期診斷、病情鑑測的價值。方法收集新診斷且未經治療的前列腺癌患者血液標本40例，前列腺增生患者血液標本21例，健康對照組患者血液標本19例，採用酶聯免疫吸附（ELISA）雙抗體夾心法分彆檢測其血清YKL-40濃度。結果前列腺癌患者組、前列腺增生患者組和健康對照組的血清YKL-40濃度分彆為（167.74±59.61）ng/ml，（118.84±25.81）ng/ml，（72.29±15.00）ng/ml，血清YKL-40濃度與臨床分期有相關性（ P＜0.01），且在前列腺癌患者轉移階段呈高度錶達，與Gleason評分無相關性。 YKL-40截斷點為120.89 ng/ml時，靈敏度為86.7％，特異度為71.4％。結論 YKL-40在前列腺癌患者血清中的濃度顯著高于前列腺增生患者和正常患者，提示檢測YKL-40對前列腺癌診斷有一定的臨床意義；血清YKL-40濃度對預測前列腺癌患者轉移可能有重要的價值，可能參與瞭前列腺癌患者轉移的過程。
목적료해YKL-40여전렬선암적발생、발전급전이적관계，지재탐토YKL-40작위종류표기물용우전렬선암조기진단、병정감측적개치。방법수집신진단차미경치료적전렬선암환자혈액표본40례，전렬선증생환자혈액표본21례，건강대조조환자혈액표본19례，채용매련면역흡부（ELISA）쌍항체협심법분별검측기혈청YKL-40농도。결과전렬선암환자조、전렬선증생환자조화건강대조조적혈청YKL-40농도분별위（167.74±59.61）ng/ml，（118.84±25.81）ng/ml，（72.29±15.00）ng/ml，혈청YKL-40농도여림상분기유상관성（ P＜0.01），차재전렬선암환자전이계단정고도표체，여Gleason평분무상관성。 YKL-40절단점위120.89 ng/ml시，령민도위86.7％，특이도위71.4％。결론 YKL-40재전렬선암환자혈청중적농도현저고우전렬선증생환자화정상환자，제시검측YKL-40대전렬선암진단유일정적림상의의；혈청YKL-40농도대예측전렬선암환자전이가능유중요적개치，가능삼여료전렬선암환자전이적과정。
Objective To understand the relationship between YKL-40 with the occurrence,development, transfer of prostate cancer ( PCa) ,and to investigate the value of YKL-40 as a tumor marker for early diagnosis and condition monitoring of prostate cancer .Methods Serum level of YKL-40 was measured with ELISA in 40 men with PCa newly diagnosed but untreated , in 21 men with benign prostatic hyperplasia , and in 19 healthy men. Results Serum YKL-40 concentration in men with PCa and benign prostatic hyperplasia , and in controls were (167.74 ±59.61)ng/ml,(118.84 ±25.81)ng/ml,and(72.29 ±15.00)ng/ml,respectively.There was statistically significant association between serum YKL-40 expression and clinical stage ( P <0.01 ) , but no correlation with Gleason scores , and it was highly expressed in the transfer process of PCa .A cut-off serum YKL-40 value of 120.89 ng/ml produced 86.7%sensitivity and 71.4%specificity .Conclusion YKL-40 in prostate cancer patients were significantly higher than in the patients with benign prostatic hyperplasia and normal ,it is an important indicator for diagnosis of patients with PCa .Serum YKL-40 concentration on prediction PCa patients transfer may have important value;It may be involved in the transfer process in patients with PCa .
